HST Global, Inc.

OTCPK:HSTC Stock Report

Market Cap: US$14.7m

HST Global Valuation

Is HSTC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of HSTC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate HSTC's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate HSTC's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for HSTC?

Key metric: As HSTC is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for HSTC. This is calculated by dividing HSTC's market cap by their current book value.
What is HSTC's PB Ratio?
PB Ratio11.9x
BookUS$1.24m
Market CapUS$14.71m

Price to Book Ratio vs Peers

How does HSTC's PB Ratio compare to its peers?

The above table shows the PB ratio for HSTC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average2.9x
NNVC NanoViricides
1.9xn/aUS$19.7m
OPGN OpGen
4.2xn/aUS$12.5m
APRE Aprea Therapeutics
0.7x-8.2%US$15.7m
AIM AIM ImmunoTech
4.6x-0.3%US$13.4m
HSTC HST Global
11.9xn/aUS$14.7m

Price-To-Book vs Peers: HSTC is expensive based on its Price-To-Book Ratio (11.9x) compared to the peer average (2.9x).

Price to Book Ratio vs Industry

How does HSTC's PB Ratio compare vs other companies in the US Biotechs Industry?

61 CompaniesPrice / BookEstimated GrowthMarket Cap
GRAL GRAIL
0.2x35.7%US$554.58m
IMAB I-Mab
0.4x1.8%US$76.59m
ACET Adicet Bio
0.4x6.7%US$74.16m
MGX Metagenomi
0.3x-23.2%US$70.73m
HSTC 11.9xIndustry Avg. 1.9xNo. of Companies81PB01.63.24.86.48+
61 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: HSTC is expensive based on its Price-To-Book Ratio (11.9x) compared to the US Biotechs industry average (1.9x).

Price to Book Ratio vs Fair Ratio

What is HSTC's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HSTC PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio11.9x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate HSTC's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Spectrum Pharmaceuticals

US$209.9m

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.

SPPI

US$1.03

7D

5.3%

1Y

17.0%

IQVIA Holdings

US$36.6b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$201.82

7D

4.7%

1Y

-4.8%

Collegium Pharmaceutical

US$966.2m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$29.96

7D

1.3%

1Y

15.1%